The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
Abstract Background Recombinant factors VIII and IX Fc (rFVIIIFc/rFIXFc) were the only available extended half‐life (EHL) products in Canada during 2016 to 2018. Objectives To evaluate if patient‐reported outcome measures (PROMs) improved in Canadian persons with hemophilia who switched from standar...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wiley
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/cdf7d3770049495c886f6d00d200190b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:cdf7d3770049495c886f6d00d200190b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:cdf7d3770049495c886f6d00d200190b2021-11-29T09:35:28ZThe impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B2475-037910.1002/rth2.12601https://doaj.org/article/cdf7d3770049495c886f6d00d200190b2021-10-01T00:00:00Zhttps://doi.org/10.1002/rth2.12601https://doaj.org/toc/2475-0379Abstract Background Recombinant factors VIII and IX Fc (rFVIIIFc/rFIXFc) were the only available extended half‐life (EHL) products in Canada during 2016 to 2018. Objectives To evaluate if patient‐reported outcome measures (PROMs) improved in Canadian persons with hemophilia who switched from standard half‐life (SHL) to EHL products (rFVIIIFc/rFIXFc). Patients/Methods This prospective cohort study enrolled persons with moderate or severe hemophilia aged ≥6 years who switched to rFVIIIFc/rFIXFc (2016‐2018) and those who remained on SHL. Health‐related quality of life (HRQoL) was assessed using the Haemophilia‐specific Quality of Life (Haem‐A‐QoL) and 36‐item Short‐Form Survey (SF‐36) at baseline, 3‐months, 12 months, and 24 months. Other PROMs included the Work Productivity and Impairment Questionnaire, chronic pain scale, partner/parent ratings of mood, International Physical Activity Questionnaire, and Treatment Satisfaction Questionnaire for Medication. We identified meaningful changes using minimally important difference for SF‐36 and responder definition for Haem‐A‐QoL. Results We enrolled 25 switchers (16 rFVIIIFc, 9 rFIXFc) and 33 nonswitchers. Those switched to rFVIIIFc/rFIXFc had improved overall HRQoL, and improved subscale physical activity, mental health, and social functioning at 3 months. The rFIXFc switchers had improved chronic pain and ability to engage in normal activities while the rFVIIIFc switchers had improved treatment satisfaction. There was no change in work impairment after the switch. Observed improvement disappeared by 24 months in most domains. Conclusion Switching from SHL to rFVIIIFc/rFIXFc resulted in short‐term meaningful improvement in overall HRQoL and other PROMs in a small proportion. Longitudinal changes on PROMs are affected by ceiling effects and response shift, warranting further studies in instrument optimization in the era of EHL and nonfactor products.Haowei (Linda) SunMing YangMan‐Chiu PoonAdrienne LeeK. Sue RobinsonMichelle SholzbergJohn WuAlfonso IorioVictor BlanchetteManuel CarcaoRobert J. KlaassenShannon JacksonWileyarticleextended half‐lifehemophilia Ahemophilia Bpatient‐reported outcomesquality of lifeDiseases of the blood and blood-forming organsRC633-647.5ENResearch and Practice in Thrombosis and Haemostasis, Vol 5, Iss 7, Pp n/a-n/a (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
extended half‐life hemophilia A hemophilia B patient‐reported outcomes quality of life Diseases of the blood and blood-forming organs RC633-647.5 |
| spellingShingle |
extended half‐life hemophilia A hemophilia B patient‐reported outcomes quality of life Diseases of the blood and blood-forming organs RC633-647.5 Haowei (Linda) Sun Ming Yang Man‐Chiu Poon Adrienne Lee K. Sue Robinson Michelle Sholzberg John Wu Alfonso Iorio Victor Blanchette Manuel Carcao Robert J. Klaassen Shannon Jackson The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B |
| description |
Abstract Background Recombinant factors VIII and IX Fc (rFVIIIFc/rFIXFc) were the only available extended half‐life (EHL) products in Canada during 2016 to 2018. Objectives To evaluate if patient‐reported outcome measures (PROMs) improved in Canadian persons with hemophilia who switched from standard half‐life (SHL) to EHL products (rFVIIIFc/rFIXFc). Patients/Methods This prospective cohort study enrolled persons with moderate or severe hemophilia aged ≥6 years who switched to rFVIIIFc/rFIXFc (2016‐2018) and those who remained on SHL. Health‐related quality of life (HRQoL) was assessed using the Haemophilia‐specific Quality of Life (Haem‐A‐QoL) and 36‐item Short‐Form Survey (SF‐36) at baseline, 3‐months, 12 months, and 24 months. Other PROMs included the Work Productivity and Impairment Questionnaire, chronic pain scale, partner/parent ratings of mood, International Physical Activity Questionnaire, and Treatment Satisfaction Questionnaire for Medication. We identified meaningful changes using minimally important difference for SF‐36 and responder definition for Haem‐A‐QoL. Results We enrolled 25 switchers (16 rFVIIIFc, 9 rFIXFc) and 33 nonswitchers. Those switched to rFVIIIFc/rFIXFc had improved overall HRQoL, and improved subscale physical activity, mental health, and social functioning at 3 months. The rFIXFc switchers had improved chronic pain and ability to engage in normal activities while the rFVIIIFc switchers had improved treatment satisfaction. There was no change in work impairment after the switch. Observed improvement disappeared by 24 months in most domains. Conclusion Switching from SHL to rFVIIIFc/rFIXFc resulted in short‐term meaningful improvement in overall HRQoL and other PROMs in a small proportion. Longitudinal changes on PROMs are affected by ceiling effects and response shift, warranting further studies in instrument optimization in the era of EHL and nonfactor products. |
| format |
article |
| author |
Haowei (Linda) Sun Ming Yang Man‐Chiu Poon Adrienne Lee K. Sue Robinson Michelle Sholzberg John Wu Alfonso Iorio Victor Blanchette Manuel Carcao Robert J. Klaassen Shannon Jackson |
| author_facet |
Haowei (Linda) Sun Ming Yang Man‐Chiu Poon Adrienne Lee K. Sue Robinson Michelle Sholzberg John Wu Alfonso Iorio Victor Blanchette Manuel Carcao Robert J. Klaassen Shannon Jackson |
| author_sort |
Haowei (Linda) Sun |
| title |
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B |
| title_short |
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B |
| title_full |
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B |
| title_fullStr |
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B |
| title_full_unstemmed |
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B |
| title_sort |
impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia a and hemophilia b |
| publisher |
Wiley |
| publishDate |
2021 |
| url |
https://doaj.org/article/cdf7d3770049495c886f6d00d200190b |
| work_keys_str_mv |
AT haoweilindasun theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT mingyang theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT manchiupoon theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT adriennelee theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT ksuerobinson theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT michellesholzberg theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT johnwu theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT alfonsoiorio theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT victorblanchette theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT manuelcarcao theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT robertjklaassen theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT shannonjackson theimpactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT haoweilindasun impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT mingyang impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT manchiupoon impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT adriennelee impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT ksuerobinson impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT michellesholzberg impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT johnwu impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT alfonsoiorio impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT victorblanchette impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT manuelcarcao impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT robertjklaassen impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab AT shannonjackson impactofextendedhalflifefactorconcentratesonpatientreportedhealthoutcomemeasuresinpersonswithhemophiliaaandhemophiliab |
| _version_ |
1718407429717229568 |